ResearcherUniversity of Massachusetts BostonActive in the last 2 years
Jonathan P. Celli
Matched on ORCID iD 0000-0003-3560-0770; OpenAlex author ID A5107115177; NIH RePORTER profile ID 10294019.
Their work
- Papers
- 8 (first author 1, last author 6)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 9
2011: 1 paper · 2012: 1 grant · 2013: none · 2014: none · 2015: 1 grant · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers
Papers 8
- Efficacy of photodynamic therapy using 5-aminolevulinic acid-induced photosensitization is enhanced in pancreatic cancer cells with acquired drug resistance. Last author DOI 10.1016/j.pdpdt.2024.104362↗
- Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging studies of 3D co-culture models. Last author DOI 10.1038/s41598-024-71372-9↗
- Photodynamic Stromal Depletion Enhances Therapeutic Nanoparticle Delivery in 3D Pancreatic Ductal Adenocarcinoma Tumor Models. Last author DOI 10.1111/php.13663↗
- Photodestruction of Stromal Fibroblasts Enhances Tumor Response to PDT in 3D Pancreatic Cancer Coculture Models. Last author DOI 10.1111/php.13339↗
- Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13174354↗
- Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Co-author DOI 10.18632/oncotarget.24425↗
- ECM Composition and Rheology Regulate Growth, Motility, and Response to Photodynamic Therapy in 3D Models of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1541-7786.mcr-16-0260↗
- Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. First author DOI 10.1002/lsm.21093↗
Grants 2
Closest collaborators
The 9 strongest of 9 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Vida Karimnia · 4 shared papers, 2021–2024
- Paper Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13174354↗
- Paper Photodynamic Stromal Depletion Enhances Therapeutic Nanoparticle Delivery in 3D Pancreatic Ductal Adenocarcinoma Tumor … DOI 10.1111/php.13663↗
- Paper Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging stu… DOI 10.1038/s41598-024-71372-9↗
- Frank John Slack · 4 shared papers, 2021–2024
- Paper Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13174354↗
- Paper Photodynamic Stromal Depletion Enhances Therapeutic Nanoparticle Delivery in 3D Pancreatic Ductal Adenocarcinoma Tumor … DOI 10.1111/php.13663↗
- Paper Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging stu… DOI 10.1038/s41598-024-71372-9↗
- Tayyaba G. Hasan · 3 shared papers, 2011–2024
- Paper Efficacy of photodynamic therapy using 5-aminolevulinic acid-induced photosensitization is enhanced in pancreatic cance… DOI 10.1016/j.pdpdt.2024.104362↗
- Paper Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer … DOI 10.18632/oncotarget.24425↗
- Paper Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. DOI 10.1002/lsm.21093↗
- Gwendolyn M. Cramer · 2 shared papers, 2017–2024
- Paper Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging stu… DOI 10.1038/s41598-024-71372-9↗
- Paper ECM Composition and Rheology Regulate Growth, Motility, and Response to Photodynamic Therapy in 3D Models of Pancreatic… DOI 10.1158/1541-7786.mcr-16-0260↗
- Yiran Liu · 1 shared paper, 2024
- Eric Struth · 1 shared paper, 2024
- Anne-Laure Bulin · 1 shared paper, 2018
- Mans Broekgaarden · 1 shared paper, 2018
- Stephen P. Pereira · 1 shared paper, 2011
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.